INZY RSI Chart
Last 7 days
1.7%
Last 30 days
-2.5%
Last 90 days
-18.7%
Trailing 12 Months
-28.9%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 02, 2024 | treco douglas a | sold | -52,209 | 6.94 | -7,523 | ceo |
Apr 01, 2024 | treco douglas a | acquired | - | - | 25,000 | ceo |
Mar 28, 2024 | winton matthew | acquired | 10,616 | 3.33 | 3,188 | coo |
Sep 29, 2023 | subramanian sanjay | acquired | 8,278 | 3.57 | 2,319 | svp, cfo |
Aug 01, 2023 | pivotal bioventure partners fund i, l.p. | bought | 4,000,000 | 4.8 | 833,333 | - |
Aug 01, 2023 | hopfner robert lorne | bought | 4,000,000 | 4.8 | 833,333 | - |
May 12, 2023 | hopfner robert lorne | bought | 1,429,390 | 6.25 | 228,702 | - |
May 11, 2023 | hopfner robert lorne | bought | 1,420,610 | 6.48 | 219,230 | - |
Mar 31, 2023 | subramanian sanjay | acquired | 2,163 | 2.21 | 979 | svp, cfo |
Mar 31, 2023 | bolte axel | acquired | 10,621 | 2.21 | 4,806 | - |
Which funds bought or sold INZY recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | Sofinnova Investments, Inc. | unchanged | - | 14,553,000 | 32,787,200 | 1.83% |
May 15, 2024 | ADAGE CAPITAL PARTNERS GP, L.L.C. | reduced | -3.77 | 17,229,300 | 40,819,000 | 0.08% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | reduced | -44.33 | 218 | 228,980 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | reduced | -22.8 | 1,506,780 | 5,389,620 | -% |
May 15, 2024 | PRELUDE CAPITAL MANAGEMENT, LLC | new | - | 478,329 | 478,329 | 0.03% |
May 15, 2024 | Laurion Capital Management LP | reduced | -27.83 | 706,607 | 3,080,830 | 0.03% |
May 15, 2024 | SPHERA FUNDS MANAGEMENT LTD. | reduced | -12.16 | 3,858,480 | 10,516,500 | 1.48% |
May 15, 2024 | NEA Management Company, LLC | unchanged | - | 8,288,140 | 18,672,700 | 1.16% |
May 15, 2024 | SAMLYN CAPITAL, LLC | reduced | -13.63 | 7,945,820 | 22,312,900 | 0.37% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -89.77 | -13,531 | 3,049 | -% |
Unveiling Inozyme Pharma, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Inozyme Pharma, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.52 | 7.43 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.1B | 2.0B | -57.61 | 9.55 | ||||
BMRN | 14.6B | 2.5B | 71.11 | 5.91 | ||||
INCY | 12.8B | 3.8B | 17.13 | 3.39 | ||||
MID-CAP | ||||||||
BBIO | 5.8B | 107.9M | -10.63 | 48.09 | ||||
APLS | 5.1B | 524.1M | -12.22 | 9.73 | ||||
AXSM | 3.7B | 251.0M | -12.4 | 14.64 | ||||
ARWR | 3.1B | 240.7M | -6.6 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.4K | 3.01 | ||||
SMALL-CAP | ||||||||
NVAX | 2.0B | 996.6M | -5.07 | 2.03 | ||||
CPRX | 1.9B | 411.3M | 29.69 | 4.7 | ||||
CRBP | 489.5M | 881.7K | -14.5 | 481.06 | ||||
INO | 330.9M | 4.9M | -2.65 | 67.99 | ||||
IBIO | 15.7M | 2.1M | -0.68 | 7.61 |
Inozyme Pharma, Inc. News
Balance Sheet | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
Assets | -11.9% | 177 | 201 | 206 | 151 | 142 | 139 | 154 | 162 | 109 | 124 | 138 | 148 | 159 | 169 | 179 | 69.00 | 48.00 |
Current Assets | -11.2% | 174 | 196 | 201 | 144 | 134 | 131 | 146 | 154 | 101 | 115 | 131 | 141 | 148 | 151 | 164 | 65.00 | 47.00 |
Cash Equivalents | -40.4% | 21.00 | 35.00 | 47.00 | 41.00 | 49.00 | 33.00 | 44.00 | 63.00 | 32.00 | 23.00 | 27.00 | 26.00 | 16.00 | 28.00 | 60.00 | 51.00 | 32.00 |
Net PPE | -10.2% | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 1.00 | 0.00 |
Liabilities | -3.7% | 58.00 | 60.00 | 45.00 | 45.00 | 38.00 | 21.00 | 19.00 | 13.00 | 15.00 | 14.00 | 12.00 | 10.00 | 10.00 | 11.00 | 11.00 | 7.00 | 3.00 |
Current Liabilities | -15.5% | 12.00 | 15.00 | 12.00 | 12.00 | 13.00 | 15.00 | 13.00 | 11.00 | 12.00 | 12.00 | 9.00 | 7.00 | 7.00 | 10.00 | 10.00 | 7.00 | 3.00 |
Long Term Debt | 0.6% | 45.00 | 45.00 | 32.00 | 13.00 | 24.00 | 4.00 | 4.00 | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | -15.4% | 119 | 140 | 160 | 106 | 103 | 118 | 135 | 149 | 94.00 | 109 | 126 | 138 | 149 | 158 | 168 | - | - |
Retained Earnings | -8.2% | -309 | -285 | -264 | -247 | -232 | -214 | -196 | -179 | -164 | -147 | -128 | -114 | -102 | -91.08 | -79.96 | -51.86 | -34.65 |
Additional Paid-In Capital | 0.4% | 428 | 426 | 425 | 353 | 336 | 333 | 331 | 329 | 259 | 257 | 255 | 253 | 251 | 249 | 248 | 2.00 | 1.00 |
Shares Outstanding | 0.1% | 62.00 | 62.00 | 62.00 | 46.00 | 44.00 | 40.00 | 44.00 | 40.00 | 24.00 | 24.00 | 24.00 | 23.00 | 23.00 | - | - | - | - |
Float | - | - | - | - | 199,466 | - | - | - | 128 | - | - | - | 245 | - | - | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 |
Cashflow From Operations | -32.7% | -24,533 | -18,487 | -18,868 | -15,548 | -17,772 | -14,400 | -14,514 | -14,687 | -14,160 | -13,444 | -12,300 | -10,033 | -12,376 | -10,875 | -10,201 | -8,633 | -6,265 | - | - | - |
Share Based Compensation | 1.1% | 1,691 | 1,673 | 1,672 | 1,600 | 2,092 | 1,886 | 1,849 | 2,185 | 1,752 | 2,022 | 1,752 | 1,813 | 1,577 | 1,273 | 786 | 120 | 129 | - | 107 | 40.00 |
Cashflow From Investing | 260.6% | 10,394 | -6,470 | -44,615 | -16,327 | 13,766 | 3,218 | -8,257 | -22,926 | 22,562 | 9,487 | 13,062 | 19,674 | 573 | -19,957 | -99,666 | 5,852 | -3,408 | - | - | - |
Cashflow From Financing | -98.7% | 159 | 12,516 | 69,715 | 23,642 | 20,096 | - | 4,215 | 68,333 | 240 | 11.00 | 237 | 112 | 249 | -986 | 118,861 | 31,932 | 5.00 | - | - | - |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 19,111 | $ 11,857 |
General and administrative | 5,234 | 6,512 |
Total operating expenses | 24,345 | 18,369 |
Loss from operations | (24,345) | (18,369) |
Other income (expense): | ||
Interest income | 2,374 | 1,327 |
Interest expense | (1,325) | (328) |
Other income (expense), net | (51) | (34) |
Other income, net | 998 | 965 |
Net loss | (23,347) | (17,404) |
Other comprehensive income (loss): | ||
Unrealized (losses) gains on available-for-sale securities | (156) | 150 |
Foreign currency translation adjustment | 10 | 19 |
Total other comprehensive income (loss) | (146) | 169 |
Comprehensive loss | (23,493) | (17,235) |
Net Income (Loss) | $ (23,347) | $ (17,404) |
Net loss per share attributable to common stockholders- basic | $ (0.38) | $ (0.4) |
Net loss per share attributable to common stockholders- diluted | $ (0.38) | $ (0.4) |
Weighted-average common shares and pre-funded warrants outstanding - basic | 61,772,279 | 43,720,578 |
Weighted-average common shares and pre-funded warrants outstanding - diluted | 61,772,279 | 43,720,578 |
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 20,618 | $ 34,588 |
Short-term investments | 145,535 | 154,001 |
Prepaid expenses and other current assets | 8,171 | 7,661 |
Total current assets | 174,324 | 196,250 |
Property and equipment, net | 1,316 | 1,466 |
Restricted cash | 311 | 311 |
Right-of-use assets | 992 | 1,126 |
Prepaid expenses, net of current portion | 0 | 1,694 |
Total assets | 176,943 | 200,847 |
Current liabilities: | ||
Accounts payable | 2,166 | 1,166 |
Accrued expenses | 9,306 | 12,610 |
Operating lease liabilities | 934 | 910 |
Total current liabilities | 12,406 | 14,686 |
Operating lease liabilities, net of current portion | 669 | 913 |
Long term debt, net | 45,032 | 44,769 |
Total liabilities | 58,107 | 60,368 |
Commitments and contingencies (Note 7) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value - 5,000,000 shares authorized at March 31, 2023 and December 31, 2023; no shares issued and outstanding at March 31, 2023 or December 31, 2023 | 0 | 0 |
Common Stock, $0.0001 par value - 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 61,816,509 shares issued and outstanding at March 31, 2024 and 61,768,771 shares issued and outstanding at December 31, 2023 | 6 | 6 |
Additional paid in-capital | 428,212 | 426,362 |
Accumulated other comprehensive income (loss) | (105) | 41 |
Accumulated deficit | (309,277) | (285,930) |
Total stockholders’ equity | 118,836 | 140,479 |
Total liabilities and stockholders’ equity | $ 176,943 | $ 200,847 |